2'-Fucosyllactose

DIETARY_SUPPLEMENT4 trials

Sponsors

Children's Hospital Medical Center, Cincinnati, Royal Berkshire NHS Foundation Trust, Advanced Protein Technologies Corporation

Conditions

Crohn DiseaseHematopoietic Stem Cell TransplantInflammatory Bowel DiseasesUlcerative ColitisWeight Loss

Phase 1

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

CompletedNCT03847467

Children's Hospital Medical Center, CincinnatiCrohn Disease, Inflammatory Bowel Diseases, Ulcerative Colitis

Start: 2019-09-20End: 2026-05-28Updated: 2026-08-06

Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

CompletedNCT04263597

Children's Hospital Medical Center, CincinnatiHematopoietic Stem Cell Transplant

Start: 2020-08-26End: 2025-05-23Updated: 2026-09-02

Unknown Phase

Prebiotics in Reducing Inflammation and Clinical Endpoints in Ulcerative Colitis (PRInCE-UC)

CompletedNCT06050811

Royal Berkshire NHS Foundation TrustUlcerative Colitis

Start: 2024-01-03End: 2025-06-17Updated: 2026-02-12

Effects of Human Milk Oligosaccharide Ingestion on Weight Loss and Markers of Health

CompletedNCT06547801

Advanced Protein Technologies CorporationWeight Loss

Start: 2023-05-04End: 2024-02-22Updated: 2024-08-14

Related Papers

P0803 Prebiotics in Reducing Inflammation and Clinical Endpoints in Ulcerative Colitis (PRInCE-UC): a randomised double-blind placebo-controlled crossover design clinical trial of the human milk oligosaccharide 2’-fucosyllactose in mild-to-moderate ulcerative colitis

Journal of Crohn s and Colitis2026-01-01

Effects of Human Milk Oligosaccharide 2′-Fucosyllactose Ingestion on Weight Loss and Markers of Health

Nutrients2024-10-0512 citations